Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III
| Autor: | Judith S. Hochman, Eric J. Topol, A Vahanian, Robert G. Wilcox, Peter B. Berger, Paul W. Armstrong, Eric R. Bates, David Hasdai, David R. Holmes, Douglas A. Criger, Erik Magnus Ohman, Robert M. Califf |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Cardiogenic shock Reteplase Thrombolysis medicine.disease Revascularization Internal medicine Shock (circulatory) medicine Cardiology Myocardial infarction complications Myocardial infarction medicine.symptom Cardiology and Cardiovascular Medicine business Fibrinolytic agent medicine.drug |
| Zdroj: | European Heart Journal. 20:128-135 |
| ISSN: | 0195-668X |
| Popis: | Results Shock occurred in 260 (5·3%) of 4921 patients randomized to alteplase and 560 (5·5%) of 10 138 patients randomized to reteplase. Of these patients, 28 (10·8%) and 55 (9·8%) randomized to alteplase and reteplase, respectively, presented with shock. In-hospital, 35% and 37% of shock patients assigned to alteplase or reteplase, respectively, underwent coronary angiography, with similar rates of percutaneous (211‐13%) or surgical (22‐3%) revascularization procedures subsequently performed. Death within 30 days occurred in 169 (65%) and 353 (63%) shock patients randomized to alteplase and reteplase, respectively (P=0·59). Of patients presenting with shock, 64% and 58% of patients randomized to alteplase or reteplase died within 30 days (P=0·59). Conclusion Compared with alteplase, reteplase did not improve outcome among patients who presented with shock or developed shock after receiving thrombolytics. The newer-generation thrombolytic agents remain of limited eYcacy in the treatment and prevention of shock. (Eur Heart J 1999; 20: 128‐135) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|